-
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials JAMA Oncol. (IF 22.5) Pub Date : 2025-06-01
Alexander D. Sherry, Avital M. Miller, Jnana Preeti Parlapalli, Gabrielle S. Kupferman, Esther J. Beck, Jordan McDonald, Ramez Kouzy, Joseph Abi Jaoude, Timothy A. Lin, Nina N. Sanford, Fumiko Chino, Bishal Gyawali, Christopher Booth, Pavlos Msaouel, Ethan B. LudmirImportanceAlternative end points, such as progression-free survival, are increasingly used in phase 3 randomized clinical trials (RCTs). However, alternative end points are often not valid surrogates for overall survival and quality of life (QOL) and may be less relevant to patients.ObjectiveTo determine the proportion of phase 3 RCTs with overall survival or QOL superiority.Design and SettingMeta-epidemiological
-
-
Are Early-Onset Cancers an Example of Accelerated Biological Aging? JAMA Oncol. (IF 22.5) Pub Date : 2025-05-29
Jennifer L Guida,Lisa Gallicchio,Paige A Green -
Coding Errors in Study of Lung Cancer Screening Guidelines and Adherence. JAMA Oncol. (IF 22.5) Pub Date : 2025-05-29
LaShae D Rolle -
Acupuncture for Nocturia in Survivors of Prostate Cancer: The NOCTURNAL Randomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2025-05-29
Kevin T Liou,Sigrid Carlsson,Divya Ajay,Jaspreet S Sandhu,Yuelin Li,Q Susan Li,Felix Cheung,Kamy Chong,Allison Booher,Katherine Han,Kaitlin Lampson,Christian Nelson,Michael J Morris,Vincent P Laudone,Jun J Mao -
Expression of Membrane Targets for Therapeutics in RET-Positive Non–Small Cell Lung Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-05-29
Arianna Marinello, Maria Rosa Ghigna, Julia K. Rotow, Tolulope Adeyelu, Giulio Metro, Mariana Brandão, Florian Guisier, Isabelle Monnet, Hortense Gaultier de Saint Basile, Carlo Genova, Judith Raimbourg, Safae Terrisse, Karine Godefroy, Luca Toschi, Martina Mandarano, Hélène Doubre, Alessandro Russo, Alexander Valent, Abdul Rafeh Naqash, Ayesha Aijaz, Anas Gazzah, Jordi Remon, Ari Vanderwalde, AndrewImportancePatients with advanced RET fusion–positive (RET+) non–small cell lung cancer (NSCLC) who experience disease progression following treatment with RET inhibitors (RETis) have limited treatment options. Identifying membrane protein targets may support the assessment of novel therapies, such as antibody-drug conjugates and bispecific antibodies.ObjectiveTo evaluate membrane target expression
-
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance JAMA Oncol. (IF 22.5) Pub Date : 2025-05-29
Thorir Einarsson Long, Saemundur Rognvaldsson, Sigrun Thorsteinsdottir, Ingigerdur Solveig Sverrisdottir, Elias Eythorsson, Jon Thorir Oskarsson, Olafur Skuli Indridason, Runolfur Palsson, Thor Aspelund, Brynjar Vidarsson, Pall Torfi Onundarson, Bjarni Agnar Agnarsson, Margret Sigurdardottir, Ingunn Thorsteinsdottir, Isleifur Olafsson, Asdis Rosa Thordardottir, Asbjorn Jonsson, Gauti Gislason, AndriImportanceRecent studies suggest standard reference intervals for serum free light chains (FLC) are inaccurate and that this problem can only be partially remedied by using separate reference intervals for individuals with impaired kidney function. This decreases the utility of FLC testing in the clinical evaluation and follow-up of plasma cell disorders, particularly affecting the diagnosis of light
-
Public Awareness of the Association Between Alcohol and Cancer in the US JAMA Oncol. (IF 22.5) Pub Date : 2025-05-29
Joël Fokom Domgue, Robert Yu, Ernest Hawk, Sanjay SheteThis population-based study examines US national survey data to identify variables associated with greater or lower awareness of alcohol and cancer risk.
-
Breast Cancer Outcomes in Transgender and Gender-Diverse Patients in the National Cancer Database JAMA Oncol. (IF 22.5) Pub Date : 2025-05-22
Kelley Chan, Joseph H. Cotler, Alexandra C. Istl, Sailaja Kamaraju, Andrew E. Petroll, Melinda Stolley, Chandler S. CortinaThis cohort study examines breast cancer outcomes in transgender and gender-diverse patients compared with cisgender patients, including overall survival and sociodemographic characteristics.
-
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-05-22
Biagio Ricciuti, Francesca Fusco, Alissa Cooper, Edoardo Garbo, Federica Pecci, Mihaela Aldea, Xinan Wang, Maria Mayoral Penalva, Michelle Ginsberg, Lynette M. Sholl, Mizuki Nishino, Alessandro Di Federico, Narek Shaverdian, Matthew Bott, Valentina Santo, Erino Rendina, Rocco Trisolini, Sara Ramella, Filippo Gallina, Enrico Melis, Simonetta Buglioni, Gabriele Minuti, Lorenza Landi, Paula A. UgaldeImportancePatients with borderline resectable or unresectable stage III non–small cell lung cancer (NSCLC) with T4 and/or N2-N3 involvement face limited treatment options and poor outcomes. Neoadjuvant chemoimmunotherapy has shown promise in improving resectability and pathological responses.ObjectiveTo evaluate the efficacy of neoadjuvant programmed cell death 1 protein (PD-1) or programmed cell death
-
Autoamputation in Mismatch Repair–Deficient Colon Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-05-22
Michael Flanagan, Michael Kelly, Paul McCormickA woman in her 50s with a history of hemochromatosis, psoriasis, and type 2 diabetes presented with a 3-month history of abdominal pain, weight loss, and a large palpable fixed abdominal mass. What is your diagnosis?
-
The Next Wave After Immunotherapy in Cancer Drug Development-Back to the Future. JAMA Oncol. (IF 22.5) Pub Date : 2025-05-22
Satya Das -
Skimming the Median and the Problem of Exaggerated Survival Gains JAMA Oncol. (IF 22.5) Pub Date : 2025-05-22
Tito Fojo, Susan BatesThis Viewpoint describes a phenomenon termed skimming the median and discusses 3 examples to emphasize why an entire dataset should be considered to reach precise conclusions.
-
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-05-22
Yazan Abboud,Kaveh Hajifathalian -
Tomosynthesis vs Digital Mammography Screening in Women with a Family History of Breast Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-05-22
Tong Li, Yu-Ru Su, Janie M. Lee, Ellen S. O’Meara, Diana L. Miglioretti, Karla Kerlikowske, Louise Henderson, Nehmat HoussamiImportanceEvidence on screening outcomes with digital breast tomosynthesis (DBT) vs digital mammography (DM) in women with a family history of breast cancer is limited.ObjectiveTo compare the performance of DBT and DM screening in women with a family history of breast cancer overall and subdivided by breast cancer family history category, breast density, age group, screening interval, and screening
-
Challenges in Shared Care Research in Hematopoietic Cell Transplantation-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-05-15
Gregory A Abel,Haesook T Kim,Robert J Soiffer -
Challenges in Shared Care Research in Hematopoietic Cell Transplant. JAMA Oncol. (IF 22.5) Pub Date : 2025-05-15
Kwok Ying Chan,Harinder Gill,Chi Yan Wong -
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy JAMA Oncol. (IF 22.5) Pub Date : 2025-05-15
John Nikitas, Leslie K. Ballas, Tahmineh Romero, Connor Lynch, Ting Martin Ma, Luca F. Valle, Ankush Sachdeva, Natalie Chong, Vince Basehart, Antonio Franco, Robert Reiter, Christopher Saigal, Karim Chamie, Mark S. Litwin, Nicholas M. Donin, Matthew Rettig, Nicholas G. Nickols, Minsong Cao, Stanley L. Liauw, Michael L. Steinberg, Amar U. KishanImportancePostoperative radiotherapy remains underused for men with biochemical recurrence or adverse pathological features after radical prostatectomy (RP). Stereotactic body radiotherapy (SBRT) may improve utilization and poses potential radiobiological advantages.ObjectiveTo evaluate physician-reported late toxic effects and 2-year patient-reported outcomes (PROs) following post-RP SBRT.Design,
-
Barriers to Chimeric Antigen Receptor T-Cell Therapy. JAMA Oncol. (IF 22.5) Pub Date : 2025-05-15
Yannis K Valtis,Kuo-Kai Chin,David Nemirovsky,Sean M Devlin,Meira Yisraeli Salman,Leora Boussi,Briana Cadzin,Carina McLoughlin,Elizabeth Cathcart,Paul Davis,Chelsea Brooklyn,Todd Goldstein,Chris Famulare,Gunjan L Shah,Moneeza Walji,Michael Scordo,Alexander P Boardman,Roni Shouval,Eytan M Stein,Mark B Geyer,Sham Mailankody,M Lia Palomba,Saad Z Usmani,Gilles Salles,Sergio A Giralt,Miguel-Angel Perales -
Can Ultra-Hypofractionated Stereotactic Radiation After Radical Prostatectomy Cut Time on Treatment or Are the Data Not Sharp Enough? JAMA Oncol. (IF 22.5) Pub Date : 2025-05-15
Sean M McBride,Howard I Scher -
Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-05-08
James Heyward, Catherine R. Lesko, Joseph C. Murray, Hemalkumar B. Mehta, Jodi B. SegalImportanceThe benefits and harms of immune checkpoint inhibitor (ICI) therapy for lung cancer vary across groups, including those typically underrepresented in randomized clinical trials.ObjectiveTo quantify the harms and benefits of ICI-containing regimens in individuals with non–small cell lung cancer and assess heterogeneity across priority subgroups.Design, Setting, and ParticipantsThis retrospective
-
Prophylactic Irradiation of the Contralateral Breast for BRCA Carriers With Early Breast Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-05-08
Ella Evron, Benjamin W. Corn, Hadassah Goldberg, Roxolyana Abdah-Bortnyak, Ora Rosengarten, Diana Matceyevsky, David B. Geffen, Raphael Catane, M. Raphael Pfeffer, Orit Kaidar-Person, Merav A. Ben DavidThis nonrandomized phase 2 clinical trial examines contralateral breast cancer risk reduction in women who choose radiation therapy or surveillance rather than mastectomy.
-
Immunotherapy With or Without Chemotherapy in Advanced NSCLC-A Delicate Balance of Harm and Benefit. JAMA Oncol. (IF 22.5) Pub Date : 2025-05-08
Giannis Mountzios -
Reconsidering the Cancer Center Accreditation Model JAMA Oncol. (IF 22.5) Pub Date : 2025-05-08
Alison S. Baskin, Samantha K. Hendren, Lesly A. DossettThis Viewpoint explores cancer center accreditation and how accommodating the diversity of cancer centers could reduce barriers to accreditation and increase patient access to accredited centers.
-
Eligibility for Cochlear Implant Candidacy Evaluation in Childhood Cancer Survivors JAMA Oncol. (IF 22.5) Pub Date : 2025-05-01
Johnnie K. Bass, Sarah E. Warren, Sydney G. Dillard, Anna Lawrence Peeples, Kendrick Li, Skye Jones, Chia-Ho Hua, Lu Xie, Siyao Liu, Kirsten K. Ness, Melissa M. Hudson, Gregory T. Armstrong, Celine Richard, Kevin R. KrullThis cross-sectional study examines the likelihood of meeting the referral criteria for a cochlear implant and the use of hearing aid among childhood cancer survivors with severe hearing loss.
-
Modeling Population-Level Impacts of Cell-Free DNA Screening for Colorectal Cancer in Canada JAMA Oncol. (IF 22.5) Pub Date : 2025-05-01
John M. Hutchinson, Yibing Ruan, Brendan J. Chia, Carl J. Brown, Robert J. Hilsden, Jonathan M. Loree, Darren R. BrennerImportanceCell-free DNA (cfDNA) testing is an emerging approach for colorectal cancer screening that has been approved in the US. The impact of cfDNA testing in the Canadian setting, assuming adherence mirroring prior real-world cfDNA work and assay performance from a Guardant Health study, is unknown.ObjectiveTo estimate how cfDNA screening impacts clinical and economic outcomes in Canada compared
-
Management of Adult Acute Lymphoblastic Leukemia JAMA Oncol. (IF 22.5) Pub Date : 2025-05-01
Hagop Kantarjian, Ibrahim Aldoss, Elias JabbourImportanceResearch in acute lymphoblastic leukemia (ALL) is translating into rapid changes in therapy and outcomes. Historically, adult ALL was treated with intensive chemotherapy extending over 2.5 to 3 years. This established tradition, accepted because of the high cure rates in childhood ALL, has been challenged by the development of highly active targeted therapies.ObservationTreatment modalities
-
There Is Nothing Benign About Reducing the Cancer Research Budget. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-29
Richard J Boxer -
Trends in Surgical Overtreatment of Prostate Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-04-28
Steven M. Monda, Timothy Demus, Salvador Jaime-Casas, Sabir Meah, Arnav Srivastava, Richard Sarle, Corinne Labardee, Khurshid R. Ghani, Kevin M. Ginsburg, Todd M. Morgan, Tudor BorzaImportanceOvertreatment of prostate cancer is a public health concern that undermines prostate cancer screening efforts.ObjectiveTo assess trends in pathologic grade on prostatectomy during the past 2 decades as a surrogate for overtreatment.Design, Setting, and ParticipantsThis retrospective cohort study examined the grade of prostate cancer on final pathology reports among patients undergoing prostatectomy
-
Representation of the Middle East and North African Region in Oncology Clinical Trials. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-24
Tarek Taha,Tomer Meirson,Ithai Waldhorn -
Comments on a Modified Classification for Immunotherapy in Progressive Diseases-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-24
Jonas Saal,Niklas Klümper -
Comments on a Modified Classification for Immunotherapy in Progressive Diseases. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-24
Xin Li,Hu Ma,Jian-Guo Zhou -
The Role of Social Media in Fueling Bias in Oncology JAMA Oncol. (IF 22.5) Pub Date : 2025-04-24
Raffaele Giusti, Gennaro Daniele, Fotios LoupakisThis Viewpoint explores the role of social media in the dissemination of medical research findings and discusses how oversight, education, and media literacy can help prevent the spread of misinformation.
-
Patient-Centered Research Through Artificial Intelligence to Identify Priorities in Cancer Care JAMA Oncol. (IF 22.5) Pub Date : 2025-04-24
Jiyeong Kim, Michael L. Chen, Shawheen J. Rezaei, Mariana Ramirez-Posada, Jennifer L. Caswell-Jin, Allison W. Kurian, Fauzia Riaz, Kavita Y. Sarin, Jean Y. Tang, Steven M. Asch, Eleni LinosImportancePatient-centered research is essential for bridging the gap between research and patient care, yet patient perspectives are often inadequately represented in health research.ObjectiveTo leverage artificial intelligence (AI) and natural language processing (NLP) to analyze a large dataset of patient messages, defining patient concerns and generating relevant research topics, and to quantify
-
Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury JAMA Oncol. (IF 22.5) Pub Date : 2025-04-24
Shruti Gupta, Ilya G. Glezerman, Jamie S. Hirsch, Api Chewcharat, Sophia L. Wells, Jessica L. Ortega, Marta Pirovano, Raphael Kim, Kevin L. Chen, Kenar D. Jhaveri, Valda D. Page, Matthew H. Abramson, Anip Bansal, Avisek Ghimire, Melanie S. Joy, Ala Abudayyeh, David E. LeafImportanceCisplatin-associated acute kidney injury (CP-AKI) is a frequent complication of cisplatin chemotherapy and is associated with considerable morbidity and mortality. Prophylactic administration of intravenous (IV) magnesium attenuates CP-AKI in animal models; however, its association with CP-AKI in humans has not been rigorously evaluated.ObjectiveTo evaluate the association of prophylactic
-
Toward a New Paradigm in Cancer Control—Integrating Individual and Population Approaches JAMA Oncol. (IF 22.5) Pub Date : 2025-04-17
William M. P. Klein, Alexander J. RothmanThis Viewpoint discusses how the integration of individual- and population-level strategies could help the scientific literature offer actionable guidance on cancer control, therefore improving public health.
-
Overall Survival in the CAIRO5 Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-17
Alexej Ballhausen,Dominik Paul Modest -
Overall Survival in the CAIRO5 Clinical Trial-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-17
Marinde J G Bond,Rutger-Jan Swijnenburg,Cornelis J A Punt -
Overall Survival in the CAIRO5 Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-17
Xiaoliang Huang,Rumao Zhong,Weizhong Tang -
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia JAMA Oncol. (IF 22.5) Pub Date : 2025-04-17
Mingming Zhang, Shan Fu, Jingjing Feng, Ruimin Hong, Guoqing Wei, Houli Zhao, Mengyu Zhao, Huijun Xu, Jiazhen Cui, Simao Huang, Xiaoyu Wu, Lianxuan Liu, Jie Sun, Wenjun Wu, Yuanyuan Zhu, Jingsong He, Yi Zhao, Zhen Cai, Weiyan Zheng, Xiujin Ye, Jimin Shi, Yi Luo, Dongrui Wang, Alex H. Chang, Yongxian Hu, He HuangImportanceA combination of tyrosine kinase inhibitors and chimeric antigen receptor (CAR) T cells has made a breakthrough in refractory or relapsed Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). However, it remains unclear if this treatment in newly diagnosed Ph-positive ALL is associated with high rates of complete molecular remission (CMR) and leukemia-free survival.ObjectiveTo
-
Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-17
Xiao Wang,John Rothen,Sida Huang,Jessica B Long,Pamela R Soulos,Sarah B Goldberg,Ronac Mamtani,Carolyn J Presley,Natalia Kunst,Shuangge Ma,Shi-Yi Wang,Cary P Gross,Michaela A Dinan -
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-04-17
Zhi Peng, Xiaotian Zhang, Han Liang, Zhichao Zheng, Zhenning Wang, Hao Liu, Jiankun Hu, Yihong Sun, Yanqiao Zhang, Han Yan, Lin Tong, Jiahui Xu, Jiafu Ji, Lin ShenImportanceEffective treatment of locally advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer remains a challenge.ObjectiveTo compare the efficacy and safety of atezolizumab plus trastuzumab plus capecitabine and oxaliplatin chemotherapy (XELOX) vs trastuzumab plus XELOX in Chinese patients with locally advanced human epidermal growth factor receptor 2 (ERBB2; formerly HER2)–positive
-
Unintended Consequences of Patient Portal Access. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-10
Dana G Rowe,C Rory Goodwin -
-
Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy JAMA Oncol. (IF 22.5) Pub Date : 2025-04-10
Marsha Reyngold, Joshua D. Schoenfeld, Eileen M. O’Reilly, Anna M. Varghese, Charlie White, Melissa Zinovoy, Paul B. Romesser, Abraham J. Wu, Carla Hajj, John J. Cuaron, Danny N. Khalil, Wungki Park, Wei Lu, Zhigang Zhang, Kenneth H. Yu, Luis A. Diaz, Christopher H. CraneImportanceSurgical resection of pancreatic ductal adenocarcinoma (PDAC) modestly improves long-term survival due to the competing risk of metastatic disease. However, postoperative morbidity often interferes with administration of systemic therapy and may be unacceptable to some patients. Ablative radiation therapy (A-RT) has emerged as an effective noninvasive local treatment in many tumor types and
-
Local Control and Extended Survival in Locally Advanced Hepatocellular Carcinoma-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-10
Laura A Dawson,Kathryn A Winter,Jennifer Moughan -
Local Control and Extended Survival in Locally Advanced Hepatocellular Carcinoma. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-10
Zhuo Song,Xuan Zheng,Weihu Wang -
National Cancer System Characteristics and Global Pan-Cancer Outcomes JAMA Oncol. (IF 22.5) Pub Date : 2025-04-10
Edward Christopher Dee, James Fan Wu, Erin Jay G. Feliciano, Frederic Ivan L. Ting, Jonas Willmann, Frances Dominique V. Ho, Bhav Jain, Urvish Jain, Jenny Chen, Fabio Ynoe Moraes, Nancy Y. Lee, Puneeth Iyengar, Paul L. NguyenImportanceApproximately 29.9 million cancer cases and 15.3 million deaths are anticipated by 2040 globally, necessitating cancer system strengthening. A greater understanding of health system factors that can be leveraged to improve cancer control may guide health system planning.ObjectiveTo evaluate predictors of improved cancer outcomes globally.Design, Setting, and ParticipantsThis pan-cancer ecological
-
Local Control and Extended Survival in Locally Advanced Hepatocellular Carcinoma. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-10
Alexander D Sherry,Ahmed O Kaseb,Ethan B Ludmir -
Local Disease Control in Patients With Pancreatic Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2025-04-10
Douglas B Evans,Beth A Erickson,William A Hall -
Chromosome 1p Loss and 1q Gain for Grading of Meningioma JAMA Oncol. (IF 22.5) Pub Date : 2025-04-04
Alexander P. Landry, Justin Z. Wang, Vikas Patil, Jeff Liu, Chloe Gui, Yosef Ellenbogen, Andrew Ajisebutu, Leeor Yefet, Qingxia Wei, Olivia Singh, Julio Sosa, Sheila Mansouri, Aaron A. Cohen-Gadol, Ghazaleh Tabatabai, Marcos Tatagiba, Felix Behling, Jill S. Barnholtz-Sloan, Andrew E. Sloan, Silky Chotai, Lola B. Chambless, Alireza Mansouri, Serge Makarenko, Stephen Yip, Felix Ehret, David Capper, DerekImportanceThe World Health Organization (WHO) classification of central nervous system tumors (CNS) grading for meningioma was updated in 2021 to include rare molecular features, namely homozygous deletions of CDKN2A or CDKN2B and TERT promotor alterations. Previous work, including the cIMPACT-NOW statement, has discussed the potential value of including chromosomal copy number alterations to help
-
Prognostic and Predictive Insights From Genomic Assays for Breast Cancer in Diverse Populations JAMA Oncol. (IF 22.5) Pub Date : 2025-04-04
Yara Abdou, Olga Kantor, Jennifer Racz, Lisa Newman, Lori J. Pierce, Eric P. WinerImportanceDespite recent declines in breast cancer mortality rates, substantial disparities persist among race and ethnicity groups. Genomic assays are crucial for understanding the biological characteristics of tumors, providing valuable insights into prognosis and treatment response. Their integration into personalized clinical decision-making has notably enhanced outcomes, making these assays particularly
-
Changes in Oncology Medication Use After Withdrawal of Accelerated Approval JAMA Oncol. (IF 22.5) Pub Date : 2025-04-03
Catherine S. Hwang, Aaron S. Kesselheim, Amar H. Kelkar, Edward R. Scheffer Cliff, Benjamin N. RomeThis cohort study assesses changes in cancer drug use after negative confirmatory trials and removal of accelerated approval indications from US Food and Drug Administration–approved labeling.
-
Management of EGFR-Variant and ALK-Positive Non–Small Cell Lung Cancer Brain Metastasis JAMA Oncol. (IF 22.5) Pub Date : 2025-04-03
Luke R. G. Pike, Helena Yu, Chad G. RusthovenThis clinical evidence synopsis summarizes the results of 3 multi-institutional cohort studies that compare tyrosine kinase inhibitors with or without stereotactic radiosurgery in patients with non–small cell lung cancer with brain metastases.
-
Formulation-Based Cost Savings with Cabozantinib Capsules JAMA Oncol. (IF 22.5) Pub Date : 2025-04-03
Austin Wesevich, Walter M. Stadler, Mark J. RatainThis Viewpoint asserts that the formulation (tablet vs capsule) and the dosage of cabozantinib can be optimized to reduce toxicities and cost while maintaining efficacy.
-
Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2025-03-28
Henry M Kuerer,Vicente Valero,Benjamin D Smith,Savitri Krishnamurthy,Emilia J Diego,Helen M Johnson,Heather Lin,Yu Shen,Anthony Lucci,Simona F Shaitelman,Melissa P Mitchell,Judy C Boughey,Richard L White,Kelly K Hunt,Wei T Yang,Gaiane M Rauch,Importance Neoadjuvant systemic therapy (NST) has been associated with pathologic complete response (pCR) in up to 60% of breast cancers (BCs). The findings of this trial question the necessity of surgery. Objective To report preplanned 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients selected with image-guided vacuum assisted biopsy (VAB). Design, Setting,
-
Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database. JAMA Oncol. (IF 22.5) Pub Date : 2025-05-01
Giorgio Caturegli,Xuan Zhu,Bryan Palis,Timothy W Mullett,Benjamin J Resio,Daniel J Boffa -
Identifying Who Is at Risk of Interval Breast Cancers. JAMA Oncol. (IF 22.5) Pub Date : 2025-05-01
Christoph I Lee,Kathryn P Lowry -
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma JAMA Oncol. (IF 22.5) Pub Date : 2025-03-27
Giulia Claire Giudice, Kathryn E. Beckermann, Paulo Siqueira Do Amaral, Brian I. RiniImportanceImmune checkpoint inhibitors have transformed the treatment landscape for metastatic renal cell carcinoma; however, the failure of first-line therapeutic strategies remains a considerable challenge. Currently, clinicians face various issues, such as managing cases in patients who progress during treatment or relapse after adjuvant immunotherapy.ObservationsThis review evaluates different
-
Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-03-27
Yuqi Zhang, Juan Rodriguez, Xinhe Mao, Felix Grassmann, Jose Tapia, Mikael Eriksson, Per Hall, Kamila CzeneImportanceMammographic screening is the only proven method for early detection and mortality reduction of breast cancer (BC). However, many patients are missed at prior screening; thus, they receive their diagnosis between the interval of screening rounds, called interval cancer (IntCa). Some IntCas are fast growing between screening rounds.ObjectiveTo investigate the incidence and proportion of IntCa